HIV self-testing for Pre-Exposure Prophylaxis

Phase-Based Progress Estimates
Victory Program, Boston, MA
Pre-Exposure Prophylaxis+3 More
HIV self-testing - Other
All Sexes
What conditions do you have?

Study Summary

This trial will offer immediate access to PrEP through point-of-care HIV self-testing, viral load confirmation, and on-site PrEP prescriptions at a Mobile Prevention Services Van to increase uptake among people who inject drugs. HIV self-testing is used to treat Pre-Exposure Prophylaxis. No patients in this trial will receive a placebo. This is the first time that HIV self-testing has been approved by the FDA for this condition.

Eligible Conditions

  • Pre-Exposure Prophylaxis
  • Drug Use
  • Opioid Use Disorder (OUD)

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Pre-Exposure Prophylaxis

Study Objectives

4 Primary · 3 Secondary · Reporting Duration: 6 months

3 months
Number of participants who continued use of PrEP at 3 months
6 months
Acceptability of PrEP rapid Access
Number of participants enrolled
Number of participants requesting a PrEP refill
Number of participants retained in the study
Number of participants who continued use of PrEP at 6 months
Number of participants who initiated PrEP

Trial Safety

Safety Progress

1 of 3

Other trials for Pre-Exposure Prophylaxis

Trial Design

1 Treatment Group

PrEP Rapid Access
1 of 1
Experimental Treatment

40 Total Participants · 1 Treatment Group

Primary Treatment: HIV self-testing · No Placebo Group · N/A

PrEP Rapid AccessExperimental Group · 3 Interventions: Dried blood spot testing, PrEP Rapid Access, HIV self-testing · Intervention Types: Other, Other, Other

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 6 months
Closest Location: Victory Program · Boston, MA
Photo of Boston 1Photo of Boston 2Photo of Boston 3
N/AFirst Recorded Clinical Trial
0 TrialsResearching Pre-Exposure Prophylaxis
0 CompletedClinical Trials

Who is running the clinical trial?

Victory ProgramsUNKNOWN
Boston Medical CenterLead Sponsor
355 Previous Clinical Trials
852,831 Total Patients Enrolled
Sabrina Assoumou, MD MPHPrincipal InvestigatorBoston Medical Center, Infectious Diseases

Eligibility Criteria

Age 18+ · All Participants · 3 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have injected at least one non-prescribed drug in the past 90 days.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.